All In Biotech

NDA 021316 · Azurity

Altoprev

Lovastatin · Oral

Discontinued

Last checked: Nov 20, 2026Latest source record: Mar 14, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2002

Jun 26, 2002

Approved uses

2

Original approval plus efficacy supplements

Registered trials

596

155 Phase 3, 24 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • ALTOPREV · LOVASTATIN 40MG · TABLET, EXTENDED RELEASE, ORAL · Discontinued
  • ALTOPREV · LOVASTATIN 10MG · TABLET, EXTENDED RELEASE, ORAL · Discontinued
  • ALTOPREV · LOVASTATIN 60MG · TABLET, EXTENDED RELEASE, ORAL · Discontinued
  • ALTOPREV · LOVASTATIN 20MG · TABLET, EXTENDED RELEASE, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Lovastatin" as an intervention, any sponsor and status, largest first.

All 596 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Altoprev (Lovastatin)

2024 spending

$1.0M

Beneficiaries

249

681 claims

Per beneficiary

$4,121

$38.31 per unit

View as table
YearSpending
2020$1,781,973
2021$1,734,180
2022$1,615,228
2023$761,791
2024$1,026,246

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 517 on PubMed

Sponsor: Azurity

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.